Breast Cancer

Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses the HOPE Study, a randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer.

International researchers from seven countries conducted a prospective study to determine risk reduction of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy and examine other factors, such as impact of this procedure on mortality and five year survival.

New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression- free survival (PFS) than placebo and exemestane in several previously unstudied patient subgroups.

Leigh A. Neumayer, MD, professor of surgery, University of Utah School of Medicine, co-director of the multidisciplinary team treating breast cancer at Huntsman Cancer Institute, discusses patient education following a breast cancer diagnosis.

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses reimbursement for survivorship visits.

Marisa Weiss, MD, founder of Breastcancer.org, discusses women's understanding of breast cancer prevention.

Patients with ductal carcinoma in situ (DCIS) who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence

Most deaths from breast cancer occur in women who have not been regularly screened and whose tumors are diagnosed at a median age 49 years, confirming the need for the greater use of annual mammography in younger women

Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses how name brands and generic brands affect drug adherence in patients with breast cancer.

Sharon Tollin, PhD, ARNP-BC, OCN®, H. Lee Moffitt Cancer Center & Research Institute, discusses research she presented at the ONS Connections Conference 2013.

Selecting the optimal treatment for postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC) remains a challenge, given a preponderance of data for several approved therapeutics

Gwen Wyatt, PhD, RN, Professor, College of Nursing, Michigan State University, describes reflexology treatment of patients with breast cancer.

More and more, as the use of maintenance therapy increases, oncology nurses are tasked with monitoring how the strategy is working for specific patients.

The decision about whether to get tested for a genetic mutation that may predispose a person to certain cancers is a difficult one for many patients to make. Even more difficult for mutation carriers is deciding whether to undergo a prophylactic surgical procedure.

Breast cancer clinicians today are faced with an ever-expanding number of older patients, yet determining the most appropriate treatment for these individuals can be challenging.

Despite progress in treating chemotherapy-induced nausea and vomiting, especially in the acute phase up to 24 hours after treatment, the condition is still one of the side effects patients fear most.

Due to the high lifetime risk of ovarian cancer and the poor ovarian cancer surveillance options available, women who carry BRCA1 or BRCA2 mutations are advised to remove their ovaries and fallopian tubes by age 40 or when childbearing is complete.

J. Michael Dixon, MD, describes a number of effective options for clinicians to help patients better manage menopausal symptoms in patients with breast cancer and improve their quality of life.

A review of several studies examining the long-term benefits of breast-conservation therapy compared with mastectomy for women with stage breast cancer.

An effective alternative to mastectomy for early stage disease regardless of age or hormone receptor status.

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types.

Does "think pink" actually raise awareness of breast cancer?

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

Forty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.

Whether surgically or medically induced, early menopause forces women to deal with a host of emotional, physical, and practical issues.

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven

Beth Baughman DuPree, MD, FACS, discussed the latest in breast cancer care at the 3rd Annual NCONN Conference.

Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy